Ares Capital (NASDAQ: ARCC), the world's largest business development corporation (BDC), attracts many income investors with its forward dividend yield of 9.9%. However, it's becoming harder to sustain that massive yield as interest rates decline. As a BDC, Ares finances "middle market" companies, which often struggle to secure loans from conventional banks because they're classified as higher-risk clients. It currently invests in 603 companies across its $29.5 billion portfolio. To reduce its credit risk, ...

Core Viewpoint - Altria Group is transitioning towards smoke-free products while maintaining a strong dividend yield and strategic business moves, supported by FDA approvals and acquisitions [1][6]. Financial Performance - Altria reported stable fundamentals with modest growth in earnings per share (EPS) in the fourth quarter, utilizing pricing power to offset volume declines [3]. - The company has a robust dividend yield of nearly 7%, reflecting its commitment to shareholder value through frequent share buybacks and a disciplined approach to leverage [3][4]. Market Position - Altria's market capitalization is approximately $109.79 billion, indicating its significant presence in the tobacco industry [4]. - The stock price is currently $65.40, with a slight increase of 0.01, or about 1.53%, and has a 52-week range of $52.40 to $68.60 [5]. Analyst Ratings - Citigroup maintains a Neutral rating for Altria, raising its price target from $57 to $65, indicating a positive outlook for the stock's future performance [2][6].

Quick Read MSTY generates income by selling options on MicroStrategy (MSTR) stock. Its 102% yield masks distributions swinging from $0.14 to $4.42. MicroStrategy stock fell 75% from $543 to $133.20 as Bitcoin dropped 41% to $64,050. Option premiums compress as MSTR falls. High yield means nothing if MSTY’s share price collapses alongside distributions. A recent study identified one single habit that doubled Americans’ retirement savings and moved retirement from dream, to reality. Read more here. ...

分组1 - The analysis approach focuses on fundamental evaluation of businesses before considering stock investments [1] - The criteria for selecting companies include above-average dividend yields, undervalued companies, and those with turnaround potential [1] - The analyst has a background in Economics and Accounting, with certifications in Certified Management Accounting (CMA CPA) and Certified Alternative Investment Analysts (CAIA) [1]

PepsiCo, Inc. (NASDAQ:PEP) will release earnings for its fourth quarter before the opening bell on Tuesday, Feb. 3.Analysts expect the company to report quarterly earnings of $2.24 per share. That’s up from $1.96 per share in the year-ago period. The consensus estimate for PepsiCo's quarterly revenue is $28.97 billion (it reported $27.78 billion last year), according to Benzinga Pro.Ahead of quarterly earnings, UBS analyst Peter Grom, on Jan. 14, maintained PepsiCo with a Buy and lowered the price target fr ...

Core Viewpoint - Pfizer is facing significant challenges that could impact its attractiveness as an investment, particularly in relation to its dividend yield and upcoming patent expirations [1] Group 1: GLP-1 Drug Development - Pfizer's stock has fallen over 50% from its 2021 highs, partly due to its lack of a GLP-1 drug, which is crucial for diabetes management and weight loss [2] - The company previously had an internal GLP-1 candidate that was dropped, leaving it behind competitors like Eli Lilly and Novo Nordisk, which have successful GLP-1 drugs on the market [3] - Pfizer is attempting to catch up by acquiring a company with a promising GLP-1 pipeline and has agreed to distribute a GLP-1 pill for a Chinese company pending approval [3][4] Group 2: Patent Expirations - Pfizer is approaching key patent cliffs, with its oncology drug Ibrance expected to face generic competition in 2027, followed by cardiovascular drugs Eliquis and Vyndaqel in 2028 [5] - The timing of new drug development and patent expirations does not always align, but 2026 is critical as it is the last year before revenues from key drugs may start to decline [6] Group 3: Dividend Concerns - Pfizer's dividend payout ratio is around 100%, raising concerns about its ability to sustain dividends amidst setbacks in GLP-1 development and upcoming patent cliffs [7] - Although dividends are paid from cash flow rather than earnings, the high payout ratio, combined with recent acquisitions and the capital-intensive nature of the pharmaceutical sector, adds to the worry [8]

Company Overview - Univest (UVSP) is headquartered in Souderton and operates in the Finance sector, with a year-to-date stock price change of 2.08% [3] - The company currently pays a dividend of $0.22 per share, resulting in a dividend yield of 2.63%, which is higher than the Banks - Northeast industry's yield of 2.42% and the S&P 500's yield of 1.36% [3] Dividend Performance - Univest's annualized dividend of $0.88 has increased by 1.1% from the previous year [4] - Over the last five years, the company has raised its dividend twice on a year-over-year basis, achieving an average annual increase of 1.61% [4] - The current payout ratio is 29%, indicating that the company distributes 29% of its trailing 12-month earnings per share as dividends [4] Earnings Expectations - The Zacks Consensus Estimate for Univest's earnings in 2026 is projected at $3.31 per share, reflecting an expected increase of 5.75% from the previous year [5] - Future dividend growth will depend on earnings growth and the payout ratio [4] Investment Considerations - Univest is considered a compelling investment opportunity due to its strong dividend profile and current Zacks Rank of 3 (Hold) [6] - Income investors are attracted to dividends for various reasons, including tax advantages and reduced overall portfolio risk [5]

Core Insights - Visa Inc. is set to release its first-quarter earnings on January 29, with analysts predicting earnings of $3.14 per share, an increase from $2.75 per share in the same period last year [1] - The consensus estimate for Visa's quarterly revenue is $10.69 billion, up from $9.51 billion reported last year [1] Dividend Insights - Visa currently has an annual dividend yield of 0.82%, translating to a quarterly dividend of 67 cents per share, or $2.68 annually [2] - To generate $500 monthly or $6,000 annually from dividends, an investment of approximately $732,108 or around 2,239 shares is required [2] - For a more modest income of $100 monthly or $1,200 annually, an investment of $146,487 or around 448 shares is necessary [2] Dividend Calculation Methodology - The calculation for the number of shares needed for desired annual income is done by dividing the income by the annual dividend payment [3] - The dividend yield is computed by dividing the annual dividend payment by the stock's current price, which can fluctuate based on stock price changes [4] Market Performance - Visa's shares increased by 0.5%, closing at $326.98 on Wednesday [5] - Cantor Fitzgerald analyst Ramsey El-Assal has initiated coverage of Visa with an Overweight rating and a price target of $400 [5]

At Cash Flow Club , we focus on businesses with strong cash generation, ideally with a wide moat and significant durability. When these companies are bought at the right time, that can be highly rewarding for us. If you are interested in joining our community, start right here !Arbor Realty Trust ( ABR ) is a mortgage REIT that is currently offering a very high dividend yield of 16%, following a steep sell-off in recent months. While the dividend is at risk of beingJonathan Weber holds an engineering degree ...

Robert Hauver, MBA, aka “Double Dividend Stocks” was VP of Finance for an industry-leading corporation for 18 years and has been investing for more than 30 years. He focuses on undercovered and undervalued income vehicles and he leads the investing group Hidden Dividend Stocks Plus.With Hidden Dividend Stocks Plus he scours the world's markets to find solid income opportunities with dividend yields ranging from 5% to 10% or more, backed by strong earnings. Features include: a portfolio with up to 40 holding ...